Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Life Sci ; 239: 117053, 2019 Dec 15.
Article in English | MEDLINE | ID: mdl-31733316

ABSTRACT

AIMS: Intracardiac injection of recombinant EphrinA1-Fc immediately following coronary artery ligation in mice reduces infarct size in both reperfused and non-reperfused myocardium, but the cellular alterations behind this phenomenon remain unknown. MAIN METHODS: Herein, 10 wk-old B6129SF2/J male mice were exposed to acute ischemia/reperfusion (30minI/24hrsR) injury immediately followed by intracardiac injection of either EphrinA1-Fc or IgG-Fc. After 24 h of reperfusion, sections of the infarct margin in the left ventricle were imaged via transmission electron microscopy, and mitochondrial function was assessed in both permeabilized fibers and isolated mitochondria, to examine mitochondrial structure, function, and energetics in the early stages of repair. KEY FINDINGS: At a structural level, EphrinA1-Fc administration prevented the I/R-induced loss of sarcomere alignment and mitochondrial organization along the Z disks, as well as disorganization of the cristae and loss of inter-mitochondrial junctions. With respect to bioenergetics, loss of respiratory function induced by I/R was prevented by EphrinA1-Fc. Preservation of cardiac bioenergetics was not due to changes in mitochondrial JH2O2 emitting potential, membrane potential, ADP affinity, efficiency of ATP production, or activity of the main dehydrogenase enzymes, suggesting that EphrinA1-Fc indirectly maintains respiratory function via preservation of the mitochondrial network. Moreover, these protective effects were lost in isolated mitochondria, further emphasizing the importance of the intact cardiomyocyte ultrastructure in mitochondrial energetics. SIGNIFICANCE: Collectively, these data suggest that intracardiac injection of EphrinA1-Fc protects cardiac function by preserving cardiomyocyte structure and mitochondrial bioenergetics, thus emerging as a potential therapeutic strategy in I/R injury.


Subject(s)
Ephrin-A1/pharmacology , Mitochondria, Heart/drug effects , Reperfusion Injury/drug therapy , Animals , Disease Models, Animal , Electrophysiologic Techniques, Cardiac/methods , Energy Metabolism , Ephrin-A1/administration & dosage , Male , Mice , Mice, Inbred Strains , Mitochondria/drug effects , Mitochondria/metabolism , Myocardial Infarction/metabolism , Myocardial Reperfusion Injury/prevention & control , Myocardium/metabolism , Myocytes, Cardiac/metabolism
2.
PLoS One ; 7(2): e32019, 2012.
Article in English | MEDLINE | ID: mdl-22363788

ABSTRACT

Cells of the neural stem cell lineage in the adult subventricular zone (SVZ) respond to brain insult by increasing their numbers and migrating through the rostral migratory stream. However, in most areas of the brain other than the SVZ and the subgranular zone of the dentate gyrus, such a regenerative response is extremely weak. Even these two neurogenic regions do not show extensive regenerative responses to repair tissue damage, suggesting the presence of an intrinsic inhibitory microenvironment (niche) for stem cells. In the present study, we assessed the effects of injection of clustered ephrin-A1-Fc into the lateral ventricle of rats with unilateral nigrostriatal dopamine depletion. Ephrin-A1-Fc clustered by anti-IgG(Fc) antibody was injected stereotaxically into the ipsilateral lateral ventricle of rats with unilateral nigrostriatal lesions induced by 6-hydroxydopamine, and histologic analysis and behavioral tests were performed. Clustered ephrin-A1-Fc transformed the subventricular niche, increasing bromodeoxyuridine-positive cells in the subventricular area, and the cells then migrated to the striatum and differentiated to dopaminergic neurons and astrocytes. In addition, clustered ephrin-A1-Fc enhanced angiogenesis in the striatum on the injected side. Along with histologic improvements, behavioral derangement improved dramatically. These findings indicate that the subventricular niche possesses a mechanism for regulating both stem cell and angiogenic responses via an EphA-mediated signal. We conclude that activation of EphA receptor-mediated signaling by clustered ephrin-A1-Fc from within the lateral ventricle could potentially be utilized in the treatment of neurodegenerative diseases such as Parkinson's disease.


Subject(s)
Dopaminergic Neurons/metabolism , Ephrin-A1/therapeutic use , Immunoglobulin Fc Fragments/therapeutic use , Neovascularization, Physiologic , Neurogenesis , Parkinson Disease/drug therapy , Parkinson Disease/physiopathology , Recombinant Fusion Proteins/therapeutic use , Animals , Behavior, Animal/drug effects , Bromodeoxyuridine/metabolism , Cell Differentiation/drug effects , Cell Movement/drug effects , Cell Tracking , Disease Models, Animal , Dopamine/metabolism , Dopaminergic Neurons/drug effects , Ephrin-A1/administration & dosage , Ephrin-A1/pharmacology , Ephrin-A4/metabolism , Humans , Immunoglobulin Fc Fragments/administration & dosage , Immunoglobulin Fc Fragments/pharmacology , Injections, Intraventricular , Lateral Ventricles/drug effects , Lateral Ventricles/metabolism , Lateral Ventricles/pathology , Mice , Neostriatum/blood supply , Neostriatum/drug effects , Neostriatum/metabolism , Neostriatum/pathology , Neovascularization, Physiologic/drug effects , Neurogenesis/drug effects , Neurons/drug effects , Neurons/metabolism , Neurons/pathology , Olfactory Bulb/drug effects , Olfactory Bulb/metabolism , Olfactory Bulb/pathology , Parkinson Disease/pathology , Rats , Receptors, Eph Family/metabolism , Receptors, Fibroblast Growth Factor/metabolism , Recombinant Fusion Proteins/administration & dosage , Recombinant Fusion Proteins/pharmacology , Signal Transduction/drug effects
3.
J Pharm Pharmacol ; 63(11): 1401-10, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21988421

ABSTRACT

OBJECTIVES: EphrinA1, the ligand of EphA2 receptor tyrosine kinase, has been proven to suppress the growth of tumours. The aim of this study was to conjugate ephrinA1 on the surface of albumin microspheres and investigate the non-small cell lung carcinoma growth and migration in vitro. METHODS: Bovine serum albumin microspheres were designed and synthesized using a natural polymer albumin by emulsification chemical cross-linking. EphrinA1 was then conjugated on the surface of microspheres by imine formation. The microspheres conjugated with ephrinA1 (ephrinA1-MS) were characterized for particle size, surface morphology, loading efficiency and stability in vitro. The ephrinA1-MS were labelled with fluorescein isothiocyanate to determine phagocytosis. In addition, the effects of ephrinA1-MS on A549 cell growth and migration were determined. KEY FINDINGS: Albumin microspheres exhibited low toxicity for A549 cells (above 90% cell viability). More than 80% of microspheres were phagocytosed within 2 h of incubation. EphrinA1-MS decreased the expression of focal adhesion kinase more effectively than recombinant ephrinA1 alone. Furthermore, ephrinA1-MS showed significant inhibition of non-small cell lung cancer migration when compared with resting cells. EphrinA1-MS attenuated the growth of tumour colonies in matrigels. CONCLUSIONS: The developed ephrinA1-MS may serve as potential carriers for targeted delivery of the tumour suppressive protein ephrinA1, with minimal cytotoxic effects and greater antitumour therapeutic efficacy against non-small cell lung cancer.


Subject(s)
Antimetabolites, Antineoplastic/pharmacology , Carcinoma, Non-Small-Cell Lung/drug therapy , Drug Delivery Systems , Ephrin-A1/administration & dosage , Lung Neoplasms/drug therapy , Microspheres , Albumins/chemistry , Animals , Blotting, Western , Cattle , Cell Line, Tumor/drug effects , Humans , Mice , Molecular Targeted Therapy , Particle Size
4.
J Physiol ; 589(Pt 7): 1725-40, 2011 Apr 01.
Article in English | MEDLINE | ID: mdl-21282286

ABSTRACT

The purpose of this study was to investigate the role of intramyocardial administration of chimeric ephrinA1-Fc in modulating the extent of injury and inflammation in non reperfused myocardial infarction (MI). Our results show that intramyocardial injection of 6 µg ephrinA1-Fc into the border zone immediately after permanent coronary artery ligation in B6129s mice resulted in 50% reduction of infarct size, 64% less necrosis, 35% less chamber dilatation and 32% less left ventricular free wall thinning at 4 days post-MI. In the infarct zone, Ly6G+ neutrophil density was 57% reduced and CD45+ leukocyte density was 21% reduced. Myocyte damage was also reduced in ephrinA1-Fc-treated hearts, as evidenced by 54% reduced serum cardiac troponin I. Further, we observed decreased cleaved PARP, increased BAG-1 protein expression, increased phosphorylated AKT/total AKT protein, and reduced NF-κB protein with ephrinA1-Fc administration, indicating improved cellular survival. Of the eight EphA receptors known to be expressed in mice (A1­A8), RT-PCR revealed that A1­A4, A6 and A7 were expressed in the uninjured adult myocardium. Expression of EphA1­A3 and EphA7 were significantly increased following MI while EphA6 expression decreased. Treatment with ephrinA1-Fc further increased EphA1 and EphA2 gene expression and resulted in a 2-fold increase in EphA4. Upregulation and combinatorial activation of these receptors may promote tissue survival. We have identified a novel, beneficial role for ephrinA1-Fc administration at the time of MI, and propose this as a promising new target for infarct salvage in non reperfused MI. More experiments are in progress to identify receptor-expressing cell types as well as the functional implications of receptor activation.


Subject(s)
Ephrin-A1/administration & dosage , Immunoglobulin Fc Fragments/administration & dosage , Myocardial Infarction/drug therapy , Recombinant Fusion Proteins/administration & dosage , Animals , DNA-Binding Proteins/metabolism , Disease Models, Animal , Ephrin-A1/genetics , Ephrin-A1/pharmacokinetics , Gene Expression , Immunoglobulin Fc Fragments/genetics , Male , Mice , Mice, 129 Strain , Myocardial Infarction/metabolism , Myocardial Infarction/pathology , Myocardium/metabolism , Myocardium/pathology , Neovascularization, Physiologic/drug effects , Poly (ADP-Ribose) Polymerase-1 , Poly(ADP-ribose) Polymerases/metabolism , Proto-Oncogene Proteins c-akt/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Receptors, Eph Family/genetics , Receptors, Eph Family/metabolism , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/pharmacokinetics , Tissue Distribution , Transcription Factor RelA/metabolism , Transcription Factors/metabolism , Troponin I/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...